NCT03762759View on ClinicalTrials.gov

Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

May 10, 2019

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2025

Conditions
Prostate Adenocarcinoma
Interventions
PROCEDURE

Computed Tomography

Undergo PET/CT

DRUG

Fluciclovine F18

Given IV

RADIATION

Gallium Ga68-labeled PSMA-11

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (3)

30303

Grady Health System, Atlanta

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta

All Listed Sponsors
collaborator

Telix Pharmaceuticals (Innovations) Pty Limited

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Emory University

OTHER